Liposome News and Research

Latest Liposome News and Research

WRAIR researchers publish results from Plasmodium vivax malaria vaccine study

Walter Reed Army Institute of Research researchers recently published the results of testing a Plasmodium vivax malaria vaccine candidate in a human challenge model.

27 Feb 2016

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Celator Pharmaceuticals, Inc. today announced that the Phase 3 clinical trial of VYXEOS (cytarabine:daunorubicin) Liposome for Injection (also known as CPX-351) in patients with untreated high-risk (secondary) acute myeloid leukemia (AML) has reached its pre-specified number of events required for the analysis of overall survival.

16 Feb 2016

CASI Pharmaceuticals receives $10.3 million in strategic financing

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs, announces it has received approximately $10.3 million in a strategic financing previously announced on September 21, 2015.

19 Jan 2016

New nanotechnology approach could transform gliomas from death sentence into treatable condition

An MRI contrast agent that can pass through the blood-brain barrier will allow doctors to detect deadly brain tumors called gliomas earlier, say Penn State College of Medicine researchers. This ability opens the door to make this fatal cancer treatable.

18 Dec 2015

Marqibo now available to leukemia patients through myTomorrows' Internet-based platform

myTomorrows (Amsterdam, the Netherlands), announced today that it has started a collaboration with Spectrum Pharmaceuticals, Inc. (Henderson, USA) to provide access to its liposome-encapsulated vincristine for treatment of Philadelphia chromosome negative acute lymphoblastic leukemia.

10 Dec 2015

New study compares outcomes from two postoperative pain control methods in knee replacement patients

A new study published today in The Journal of the American Osteopathic Association compared outcomes from two types of postoperative pain control methods in a group of patients who had both of their knees replaced.

1 Dec 2015

Crucial tumor-suppressing gene protects immune attack against lung cancer

A crucial tumor-thwarting gene protects an immune attack against lung cancer by blocking the key to an off switch on T cells, the customized warriors of the immune system, a team led by researchers at The University of Texas MD Anderson Cancer Center reports in the Journal of the National Cancer Institute.

21 Nov 2015

New nanocarriers may effectively deliver therapeutic drug to GBM tumors

Glioblastoma multiforme, a cancer of the brain also known as "octopus tumors" because of the manner in which the cancer cells extend their tendrils into surrounding tissue, is virtually inoperable, resistant to therapies, and always fatal, usually within 15 months of onset.

20 Nov 2015

CASI reports net loss of $1.6 million for third quarter 2015

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, today reported financial results for the three and nine months ended September 30, 2015.

13 Nov 2015

Liposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman

For about the last 25 years, the cardiology group here have been developing a platform technology for both the diagnosis and treatment of atherosclerosis.

From Beckman Coulter Life Sciences - Particle Counting and Characterization 28 Oct 2015

Novel therapy gets FDA approval for patients with metastatic pancreatic adenocarcinoma

Today, The U.S. Food and Drug Administration approved a novel therapy for patients with metastatic pancreatic adenocarcinoma – the most common form of pancreatic cancer – whose disease has progressed following gemcitabine-based therapy, offering new hope against a disease that will claim the lives of more than 40,000 individuals this year.

23 Oct 2015

New combination treatment approved by FDA for metastatic pancreatic cancer

The U.S. Food and Drug Administration today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.

23 Oct 2015

CWRU investigator receives $2.82 million NIH grant to make stealth bombs for brain cancer treatment

A Case Western Reserve University researcher has received a 5-year, $2.82 million National Institutes of Health grant to make, in essence, stealth bombs that slip past the brain's defenses to attack an incurable form of cancer.

15 Oct 2015

Researchers come up with new design for a better liposome

Using computational modeling, researchers at Carnegie Mellon University, the Colorado School of Mines and the University of California, Davis have come up with a design for a better liposome. Their findings, while theoretical, could provide the basis for efficiently constructing new vehicles for nanodrug delivery.

14 Oct 2015

CASI reports financial results for second quarter 2015

14 Aug 2015

New review points to most promising areas for liposomes' further development

An international group of scientists, including Vladimir Chupin, head of the Biophysics Section at MIPT, and Vladimir Torchilin (Northeastern University, the USA), one of the world's leading experts in pharmacology, recently presented a review of liposomes, microscopic capsules widely used all over the world in the development of new drugs.

11 Aug 2015

Vaccine containing virus-like nanoparticles could be novel treatment option for RSV

A vaccine containing virus-like nanoparticles, or microscopic, genetically engineered particles, is an effective treatment for respiratory syncytial virus (RSV), according to researchers at Georgia State University.

4 Aug 2015

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that ZEVALIN is now available at hospitals in Hong Kong to patients with indicated non-Hodgkin's lymphoma (NHL), including at Hong Kong Sanatorium & Hospital.

20 Jul 2015

CASI files application with CFDA to conduct ENMD-2076 Phase 2 trial in fibrolamellar carcinoma patients

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announced today that it has filed an application with China's Food and Drug Administration to conduct a Phase 2 clinical trial in fibrolamellar carcinoma (FLC) patients in China for its proprietary drug candidate, ENMD-2076.

4 Jun 2015

Trabectedin may be better than dacarbazine for treatment of soft tissue sarcoma

Janssen Research & Development, LLC announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival with trabectedin (YONDELIS®) compared to dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with an anthracycline and at least one additional chemotherapy regimen.

2 Jun 2015